Showing 1661-1670 of 8179 results for "".
DermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PAn Excellent Networking Opportunity: DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/an-excellent-networking-opportunity-derm2021/19963/From opportunities to connect and network with other NPs and PAs to going to sessions presented by some of her favorite dermatologists, such as Ted Rosen, MD, to learn about what’s in the pipeline and coming to market soon, Leigh Ann Pansch, MSN, FNP-BC, DCNP is excited to attend the DERM2021 NP/PAThe Expanding Role for PD-1 Inhibitors for NMSCs
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-expanding-role-for-pd-1-inhibitors-for-nmscs/19937/The pool of potential patients that could be treated with PD-1 inhibitors is growing. Todd Schlesinger, MD discusses how these drugs may be used to treat a greater number of patients with NMSCs and addresses side effects and their management.Scientifically Speaking: Can We Conquer Cellulite?
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-can-we-conquer-cellulite/19872/Treating cellulite has been a challenge, but new and emerging technologies offer hope to overcome this common condition. Host Joel L. Cohen, MD talks with Nazanin Saedi, MD, Endo's Mike McLane, PhD, and Soliton's Wally Klemp.Conversations in Acne, Part 1
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-1/19867/As treatment options for acne expand, clinicians consider the potential to combine topical therapies or pair topicals with systemics, all while adhering to guidelines for care and prescribing antibiotics responsibly. In the first episode of this three-part series, host Neal Bhatia, MD speaks with HiCrisis Management: Office Operations, Part 2
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-2/18182/Practice shut downs for COVID-19 will have long-term consequences for medical aesthetic practices. Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD share their predictions with host Neal Bhatia, MD.IL-23 Inhibitors: Update on Safety and Dosing
https://practicaldermatology.com/topics/psoriasis/il-23-inhibitors-update-on-safety-and-dosing/19773/With more experience using IL-23 inhibitors to treat psoriasis, dermatologists are seeing high levels of patient satisfaction and no new safety signals. Jennifer Cather, MD assesses the clinical experience.Inclusion is In
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/inclusion-is-in/19704/Until you know your biases, you can't address them, says Jeanine Downie, MD. Inspired by the Obagi Skinclusion inititiative, she addresses the problem of bias in aesthetic medicine.Get Real: People Matter
https://practicaldermatology.com/topics/practice-management/get-real-people-matter/19678/Successful and rewarding practice may have more to do with the people you work with than any other factor, says Eric Bernstein, MD. He recaps a session he participated in to prepare residents for practice.